A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Condition(s):Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-HodgkinLast Updated:March 22, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-HodgkinLast Updated:March 22, 2017Completed
Condition(s):CD30 Positive Primary Mediastinal Large B-cell Lymphoma; CD30-Positive Diffuse Large B-Cell Lymphoma; CD30-Positive Gray Zone LymphomaLast Updated:January 5, 2021Completed
Condition(s):Lymphoma, B-cell; Lymphoma, Large B-cell, DiffuseLast Updated:June 21, 2018Terminated
Condition(s):Hodgkin DiseaseLast Updated:February 12, 2019Completed
Condition(s):Lymphatic DiseasesLast Updated:May 27, 2021Terminated
Condition(s):NK/T Cell Lymphoma NosLast Updated:April 7, 2022Not yet recruiting
Condition(s):Disease, HodgkinLast Updated:May 14, 2021Completed
Condition(s):Hodgkin LymphomaLast Updated:October 27, 2014Unknown status
Condition(s):Hodgkin LymphomaLast Updated:December 22, 2020Completed
Condition(s):T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepato-splenic T-cell Lymphoma; Adult T-cell Leukemia/Lymphoma; Enteropathy Associated T-cell Lymphoma; NK T-cell LymphomaLast Updated:February 20, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.